First report for the electrochemical investigation of a new HIV integrase inhibitor dolutegravir: Its voltammetric determination in tablet dosage forms and human urine using a boron-doped diamond electrode

In this paper, for the first time, the study of electrochemical investigation and voltammetric determination of HIV integrase inhibitor dolutegravir was described. The effect of pretreatment (anodically or cathodically) of borondoped diamond electrode was investigated in detail on the stripping voltammetric performance for this compound. Dolutegravir presented one or two oxidation peaks within the pH range 2.0-12.0 by using both pretreated electrodes. Employing square-wave stripping mode on the surface of cathodically pretreated boron-doped diamond electrode (after 60 s accumulation at +0.3 V) in Britton-Robinson buffer at pH 10.0, there was a linear dependence of the peak current at +0.79 V (vs. Ag/AgCl, 3 M NaCl) and dolutegravir concentration in the range of 1.0-50.0 mu g mL(-1) (2.38 x 10(-6) -1.19 x 10(-4) M), with a detection limit of 0.26 mu g mL(-1) (6.20 x 10(-7) M). The applicability of the developed approach for the quantification of dolutegravir was tested in the commercial tablet formulations and model human urine samples.

Automated summary

This study describes the electrochemical investigation and voltammetric determination of the HIV integrase inhibitor dolutegravir for the first time. Results showed that using cathodically pretreated boron-doped diamond electrode, a linear detection of dolutegravir can be achieved under suitable conditions.